מירנה
הערות שוליים

↑  מאגר התרופות, אגף הרוקחות במשרד הבריאות
↑  עלון לצרכנית, מאגר התרופות, אגף הרוקחות במשרד הבריאות
↑  Effectiveness of Long-Acting Reversible Contraception, NEJM 2012
↑  74 28833 01 פרטי הכללה בסל התרופות, אתר משרד הבריאות
↑  דימום וסת מוגבר, מכבי
↑  Luis Bahamondes, M Valeria Bahamondes, Ilza Monteiro. (2008), "Levonorgestrel-releasing intrauterine system: uses and controversies.", Expert Review of Medical Devices 4: 437
↑  Petta C, Ferriani R, Abrao M, Hassan D, Rosa E Silva J, Podgaec S, Bahamondes L (2005). "Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis.". Hum Reprod 20 (7): 1993–8. doi:10.1093/humrep/deh869. PMID 15790607
↑  נייר עמדה 105, "התקן תוך רחמי", האיגוד הישראלי למיילדות וגינקולוגיה
↑  נייר עמדה של איגוד רופאי הילדים האמריקאי בעניין העדפת אמצעי מניעה לטווח ארוך
↑  נייר עמדה של האיגוד הגינקולוגי האמריקאי בעניין הרחבת השימוש באמצעי מניעה לטווח ארוך
↑  המלצת ה-CDC בעניין אמצעי מניעה לטווח ארוך בנערות ונשים צעירות
↑  Luukkainen, T. (1991), "Levonorgestrel-Releasing Intrauterine Device", Annals of the New York Academy of Sciences 262: 43–49
↑  FDA Medical Review p.6
↑  Interfering with sperm transport and with ovulation, Contraception 2006
↑  Ortiz, María Elena; Croxatto, Horacio B. (June 2007). "Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action". Contraception 75 (6 Suppl): S16‒S30. doi:10.1016/j.contraception.2007.01.020. PMID 17531610. p. S28
↑  ESHRE Capri Workshop Group (2008). "Intrauterine devices and intrauterine systems". Human Reproduction Update 14 (3): 197‒208. doi:10.1093/humupd/dmn003. PMID 18400840. Unknown parameter |momth=ignored (help) p. 199:
↑  Speroff, Leon; Darney, Philip D. (2011). "Intrauterine contraception". A clinical guide for contraception (5th ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 239–280. ISBN 978-1-60831-610-6. pp. 246–247
↑  [[:en:IUD with progestogen|Jensen, Jeffrey T.; Mishell, Daniel R. Jr. (2012). "Family planning: contraception, sterilization, and pregnancy termination". In 6th, Gretchen M.; Lobo, Rogerio A.; Gershenson, David M. et al. Comprehensive gynecology. Philadelphia: Mosby Elsevier. pp. 215–272. ISBN 978-0-323-06986-1. More than one of |editor1-last= and |editor= specified (help); |displayeditors= suggested (help) p. 259:]]
↑  JMunuce, MJ; Nascimento, JAA; Rosano, G; Faundes, A; Bahamondes, L (2006), "Does of levonorgestrel comparable to that delivered by levonorgestrel-releasing uterine system can modify the in vitro expression of zona binding sites of human spermatozoa", Contraception 73 (1): 97–101
↑  Silverberg, SG; Haukkamaa, M; Arko, H, Nilsson, CG; Luukkainen, T (1986), "Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices", Int. J. Gynecol. Pathol. 5 (3): 235–241
↑  Guttinger, A; Critchley, HO (2007), "Endometrial effects of intrauterine levonorgestrel", Contraception 75 (6 Suppl.): S93–S98
↑  Sivin, I; Schmidt, F. (1987), "Effectivenss of IUDs: a review", Contraception 36: 55–84
↑  Alvarez, F; Brache, V.; Fernandez, E; Guerrero, B; Guiloff, E; Hess, R; et al. (1988), "New insights on the mode of action of intrauterine contraceptive devices in women", Fertil Steril 49: 768–773
↑  Sivin, I; Stern, J; Coutinho, E; Mattos, CE; el Mahgoub, S; Diaz, S, et al. (1991), "Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS", Contraception 44: 473–480
↑  Winner, B; Peipert, JF; Zhao, Q; Buckel, C; Madden, T; Allsworth, JE; Secura, GM. (2012), "Effectiveness of Long-Acting Reversible Contraception", New England Journal of Medicine 366 : 1998–2007, doi:10.1056/NEJMoa1110855, PMID 22621627
↑  Adherence to the oral contraceptive pill: a cross-sectional survey
↑  Mohllajee, AP; Curtis, KM; Herbert, PB. (2006), "Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review", Contraception 73 (2): 145–153
↑  Mansour, D; Gemzell-Danielsson, K; Inki, Pirjo; Jensen, JT. (2011), "Fertility after discontinuation of contraception: a comprehensive review of the literature", Contraception 84 (5): 465–477
↑  Randic, L; Vlasic, S; Matrljan, I; Waszak, C (1985), "Return to fertility after IUD removal for planned pregnancy", Contraception 32 (3): 253–259
↑  Centers for Disease Control and Prevention (2010), United States Medical Eligibility Criteria for Contraceptive Use. Unknown parameter |html=ignored (help)
↑  Thiery, M (1997), "Pioneers of the intrauterine device", The European Journal of Contraception and Reproductive Healthcare 2 (1): 15–23
↑  MIRENA® Data Sheet, Bayer NZ, 11 December 2009 http://www.bayerresources.com.au/resources/uploads/DataSheet/file9503.pdf Retrieved 2011-02-10
↑  Wong AY, Tang LC, Chin RK (2010). "Levonorgestrel-releasing intrauterine system (Mirena) and Depot medroxyprogesterone acetate (Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis: a randomised controlled trial.". Aust N Z J Obstet Gynaecol 50 (3): 273–9. doi:10.1111/j.1479-828X.2010.01152.x. PMID 20618247
↑  Bahamondes MV, Monteiro I, Castro S, Espejo-Arce X, Bahamondes L (2010). "Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system.". Hum Reprod 25 (5): 1158–64. doi:10.1093/humrep/deq043. PMID 20185512
| --- | --- |
בקרת זהויות :  NKC: ph413834 
הבהרה: המידע בוויקיפדיה נועד להעשרה בלבד ואינו מהווה ייעוץ רפואי.